APP and Alzheimer disease: The mechanism by which the variants in the receptor, SorLA, may be associated with AD are the following: 1) APP binds through the LDL domain and can redirect it to the non-amyloidogenic pathway, inhibiting the formation of beta-amyloid peptide, and 2) binds to nascent beta-amyloid peptides and directs them to the lysosome, preventing their secretion [104,106,121,123–125].